Banerjee, Abhijit (1992), “A Simple Model of Herd Behavior”, The Quarterly Journal of Economics 107 (3), pp. 797–817.CrossRefGoogle Scholar

Bentham, Jeremy ([1791] 1999), Political Tactics, Oxford, Clarendon Press.Google Scholar

Bentham, Jeremy, and Dumont, Etienne ([1791] 1822), Tactique des assemblées législatives, 2nd edition, Paris, Bossange Frères.Google Scholar

Callender, Steven (2007), “Bandwagons and Momentum in Sequential Voting”, Review of Economic Studies, 74, pp. 653–84.Google Scholar

Carpenter, Daniel (2010), Reputation and Power: Organization Image and Pharmaceutical Regulation at the FDA, Princeton, NJ, Princeton University Press.Google Scholar

Center for Science in the Public Interest (CSPI) (2005), “Conflicts of Interest on COX-2 Panel”, available on www.cspinet.org/new/200502251.html (accessed January 21, 2010).Google Scholar

Chazel, François (1992), “Pouvoir”, in Traité de Sociologie (sous la direction de Raymond Boudon), Paris, P.U.F., pp. 195–226.Google Scholar

Condorcet ([1788] 1986), “Essais sur la constitution et les fonctions des assemblées provinciales”, in Sur les Elections, Paris, Fayard, pp. 275–435.Google Scholar

Crozier, Michel, and Friedberg, Erhard (1980), Actors and Systems: The Politics of Collective Action, Chicago, The University of Chicago Press.Google Scholar

Elster, Jon (2007), Explaining Social Behavior, Cambridge, Cambridge University Press.CrossRefGoogle Scholar

Elster, Jon (2013), Securities against Misrule: Juries, Assemblies, Elections, Cambridge, Cambridge University Press.CrossRefGoogle Scholar

Food and Drug Administration (2008), Guidance for FDA Advisory Committee Members and FDA Staff: Voting Procedures for Advisory Committee Meetings, U.S. Department of Health and Human Services, Food and Drug Administration, August, 6 p., available at www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM125641.pdf (accessed February 18, 2015).Google Scholar

Friedberg, Erhard (1997), Local Orders. Dynamics of Organized Action, trans. by Yang, Emoretta, Greenwich, CT, JAI Press.Google Scholar

Gaudemet, Jean (1979), Les élections dans l'Eglise latine. Des origines au XVIe siècle, Paris, Ed. Fernand Lanore.Google Scholar

Harris, Gardiner, and Berenson, Alex (2005), “10 Voters on Panel Backing Pain Pills Had Industry Ties”, The New York Times, February 25.Google Scholar

Lurie, Peter, Almeida, Cristina M., Stine, Nicholas, Stine, Alexander R., and Wolfe, Sidney M. (2006), “Financial Conflict-of-Interest Disclosure and Voting Patterns at Food and Drug Administration Drug Advisory Committee Meetings”, Journal of the American Medical Association, 295, pp. 1921–28.Google ScholarPubMed

Malone, M.A. (2005), “Inside the FDA Panel on Cox-2 Inhibitors: More United Than Not”, Stanford Medicine Magazine, 22, 2 (Summer 2005).Google Scholar

McComas, K., Tuit, L., and Sherman, L. (2005), “Conflicted Scientist: The ‘Shared Pool’ Dilemma of Scientific Advisory Committees”, Public Understanding of Science, 1, pp. 285–303.CrossRefGoogle Scholar

Moffitt, Susan. L. (2010), “Promoting Agency Reputation through Public Advice: Advisory Committee Use in FDA”, The Journal of Politics, 72, 3, pp. 880–93.CrossRefGoogle Scholar

Moffitt, Susan L. (2012), “The Policiy Impact of Public Advice: The Effects of Advisory Committee Transparency on Regulatory Performance”, in Coglianese, C., Regulatory Breackdown? The Crisis of Confidence in U.S. Regulation, University Park, University of Pennsylvania Press.Google Scholar

O'Riordan, Michael (2009), “Mistakes Made: FDA Acknowledges Lilly Phoned to Question Sanjay Kaul's Inclusion on Prasugrel Panel”, heartwire, February 20 (accessed March 23, 2010).Google Scholar

Quéré, Louis (2005), “Les ‘dispositifs de confiance’ dans l'espace public”, Réseaux, 4, 132, pp. 185–217.CrossRefGoogle Scholar

Rettig, Richard, Earley, Laurence, and Merrill, Richard (eds.) (1992), Food and Drug Administration Advisory Committees, Washington, DC, National Academy Press.Google Scholar

Ricoeur, Paul (1966 [2007]), Freedom and Nature: The Voluntary and Involuntary, Evanston, IL, Northwestern University Press.Google Scholar

Rousseau, J.J. ([1764] 1964), Lettres écrites de la montagne, Paris, Ed. Gallimard, Bibliothèque de la Pléiade, T.III.Google Scholar

Tapley, Asa, Lurie, Peter, and Wolfe, Sidney (2006), “Suboptimum Use of FDA Advisory Committees”, Lancet, 368 (December 23), p. 2210.CrossRefGoogle Scholar

Urfalino, Philippe (2012), “Reasons and Preferences in Medicine Evaluation Committees”, in Landemore, H. and Elster, J. (eds), Collective Wisdom, Cambridge, Cambridge University Press, pp. 173–202.CrossRefGoogle Scholar

Usdin, Steve (2009), “FDA Reviewing Intellectual Bias”, BioCentury, April 20.Google Scholar

Warren, M. (1999), “Democratic Theory and Trust”, in Warren, M. (ed.), Democracy and Trust, Cambridge, Cambridge University Press.CrossRefGoogle Scholar

Zuckerman, Diana M. (2006), FDA Advisory Committees: Does Approval Mean Safety? Washington, DC, National Research Center for Women and Families.Google Scholar